-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Author Index: Q

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Qamar, A.
2662 - Alloantibody Levels, Immunoglobulin Degradation Products, and Platelet Transfusion Response over Successful Desensitization of Severe Alloimmune Platelet Refractoriness with a Novel IgG-Targeted Enzyme Therapeutic
Qamar, A.
1782 - Wild-Type Calreticulin Downmodulates MPL and Impacts HSC Self-Renewal
Qasim, A.
792 - Sickle Cell Disease Education in Low and Middle Income Countries Using a Smartphone Clinical Case Discussion App
Qasrawi, A.
2221 - Hyperbaric Oxygen (HBO) Effects on Blood Count Recovery and Post-Transplant Outcomes Following High-Dose Therapy and Autologous HSPC Transplantation for Multiple Myeloma: A Multicenter Phase II Randomized Clinical Trial
2858 - Distinct Clinical and Genetic Features of Acute Myeloid Leukemia (AML) in Obese Vs. Non-Obese Patients: A Comparative Study
Qatanani, M.
3839 - Selective Inhibition of Repulsive Guidance Molecule C/Hemojuvelin (RGMc/HJV) with SRK-256 to Mobilize Iron in Functional Iron Deficiency
Qayed, M.
776 - Flares of Acute Graft-Versus-Host Disease: Mount Sinai Acute Gvhd International Consortium (MAGIC) Study
779 - A Day 14 Endpoint for Acute Gvhd Clinical Trials
2133 - Risk Factors and Outcomes for Hematotoxicity Following Tisagenlecleucel for Pediatric B-Acute Lymphoblastic Leukemia
2153 - Age, Gvhd Prophylaxis, and Timing Matter in Thrombotic Microangiopathy after Hematopoietic Cell Therapy- a Secondary CIBMTR Analysis
3576 - The MAGIC Algorithm Probability Predicts Long-Term Outcomes and Treatment Response to Second-Line Therapy for Acute Gvhd
- Novel Approaches to Acute GVHD Prevention
Qayum, N.
3052 - GLOBRYTE: A Phase III, Open-Label, Multicenter, Randomized Trial Evaluating Glofitamab Monotherapy in Patients with Relapsed or Refractory Mantle Cell Lymphoma
3085 - Glofitamab Plus R-CHOP Induces High Response Rates with a Manageable Safety Profile in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A 12-Month Analysis from a Phase Ib Study
Qazilbash, M. H.
233 - Addition of Inotuzumab Ozogamicin to the Conditioning Regimen of Allogeneic Stem Cell Transplantation (allo-SCT) for Relapsed CD22 (+) Lymphoid Malignancies: Long-Term Survival Results
774 - Innate Cell Engager (ICE®) AFM13 Combined with Preactivated and Expanded (P+E) Cord Blood (CB)-Derived Natural Killer (NK) Cells for Patients with Refractory CD30-Positive Lymphomas: Final Results
2215 - Impact of Pre-Transplant Minimal Residual Disease in Patients with Multiple Myeloma with ≥ Very Good Partial Response Receiving Autologous Hematopoietic Stem Cell Transplantation
3356 - Impact of Revised International Staging System 2 (R2-ISS) Risk Stratification on Outcomes of Patients with Multiple Myeloma Receiving Autologous Hematopoietic Stem Cell Transplantation
3794 - Attrition after Referral for Chimeric Antigen Receptor T-Cell (CAR-T) Products in Multiple Myeloma (MM)
4712 - Safety and Efficacy Outcomes for Patients with High-Risk Multiple Myeloma Receiving Idecabtagene Vicleucel: The MD Anderson Experience
4784 - The Impact of Melphalan Conditioning Schedule on Post-Transplant Outcomes in AL Amyloidosis: A Multicenter Study with 1718 Patients
4920 - Incidence and Risk Factors of Veno-Occlusive Disease Are Different in Younger Versus Older Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
4962 - Trends in Outcomes over Three Decades after Upfront Autologous Stem Cell Transplant for Multiple Myeloma at MD Anderson Cancer Center
4963 - Outcomes of Patients with Multiple Myeloma and 1q Gain/Amplification Receiving Autologous Hematopoietic Stem Cell Transplant: The MD Anderson Cancer Center Experience
4972 - Phase 1/2 Trial to Jointly Optimize Dose and Administration Schedule of Evomela in Newly Diagnosed Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation
4988 - Patient Characteristics and Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Qi, J.
84 - Pre-Clinical Study on the Dual BCL2/BCL-XL Inhibitor AZD0466 for the Treatment of Chronic Lymphocytic Leukemia
Qi, J.
3635 - Discovery of First-in-Class Small Molecule Inhibitors of the IRF4-PU.1/Spi-B Interaction
Qi, J.
1229 - Discovery of BT-114143, a Novel and Potent Small-Molecule Plasminogen Inhibitor for Hyperfibrinolysis
Qi, J.
1900 - Updated Efficacy and Safety Results of Lisaftoclax (APG-2575) in Patients (Pts) with Heavily Pretreated Chronic Lymphocytic Leukemia (CLL): Pooled Analyses of Two Clinical Trials
1978 - A Phase 1 First-in-Human Monotherapy Study of F182112, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed or Refractory Multiple Myeloma
2908 - A Phase I/II Trial of the FLT3 Kinase Inhibitor XY0206 in Patients with Relapsed/Refractory Acute Myeloid Leukemia
3033 - Safety and Efficacy Results from the Phase I Study of a Novel Dual Covalent and Non-Covalent Next Generation Inhibitor of Bruton’s Tyrosine Kinase LP-168 in Patients with Relapsed/Refractory Mantle Cell Lymphoma
4400 - A Novel Dual Covalent and Non-Covalent Next Generation Inhibitor of Bruton’s Tyrosine Kinase LP-168 in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma: Safety and Efficacy Results from a Phase 1 Study
Qi, Q.
634 - First-Line Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O): 55-Month Follow-up from the Glow Study
Qi, S.
3597 - Upfront Autologous Stem Cell Transplant at First Complete Remission in Patients with Advanced-Stage Extra-Nodal NK/T Cell Lymphoma: A Multicenter Retrospective Study
Qi, Y.
4844 - Efficacy and Safety of BCMA-Specific CAR T Cell-Based Therapy in Relapsed/Refractory Multiple Myeloma Patients with Extramedullary Disease
Qian, C.
4207 - Dynamic Changes in ABL1 Kinase Domain Mutations and Comparative Efficacy of Third-Generation Tyrosine Kinase Inhibitors across Different Stages in Acute Lymphoblastic Leukemia and Chronic Myeloid Leukemia Blast Crisis Patients
Qian, C.
889 - Efficacy and Safety of Interleukin-6-Knockdown CD19-Targeted CAR T Cells(ssCART-19) for Relapsed/Refractory B-ALL
1506 - Venetoclax, Cladribine and Cytarabine for the Treatment of Relapse/Refractory Acute Lymphoblastic Leukemia: Interim Analysis of a Phase 2 Trial
3477 - Phase I Open-Label Single-Arm Study of Sscart-19 in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in China
3481 - Safety and Efficacy of CD22/ CD19 CAR-T and Auto-HSCT “Sandwich" Strategy As Consolidation Therapy for Ph Negative B Cell Acute Lymphoblastic Leukemia
4991 - Maintenance Therapy with Chidamide Plus Azacitidine after Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Acute Myeloid Leukemia Patients
Qian, D.
3462 - Senza5TM CART5: An Autologous CD5-Deleted Anti-CD5 CART Product with Enhanced Anti-T-Cell Lymphoma Activity
Qian, H.
1786 - Role of Lama4 Expression in Bone Marrow Niche for the Progression and Treatment Response of Chronic Myeloid Leukemia
2707 - Protective Function of Human Skin Mesenchymal Niches for Acute Myeloid Leukemia-Initiating Stem Cells
Qian, J.
2869 - Venetoclax Combined with Hag Regimen in Newly Diagnosed ETP-ALL: Interim Analysis of a Prospective, Multicenter, Phase 2 Trial
2912 - Venetoclax Plus ‘2 + 5’ Modified Intensive Chemotherapy with Daunorubicin and Cytarabine in Fit Elderly Patients with Untreated De Novo Acute Myeloid Leukaemia: A Single-Centre Retrospective Analysis
Qian, L.
1769 - Simplified Geriatric Assessment-Albumin: The Modified Tool for Older Diffuse Large B-Cell Lymphoma in China
Qian, P.
7 - Bromodomain Protein BRD4 Is a Transcriptional Repressor of Terminal Erythropoiesis By Interacting with EHMT1/2
101 - A Multi-Omic Single-Cell Landscape of Cytokine Release Syndrome in Multiple Myeloma Patients after Anti-BCMA CAR-T Cell Therapy
142 - The ATF4-RPS19BP1 Axis Modulates Ribosome Biogenesis to Promote Erythropoiesis
366 - Deciphering the Impact of Donor Telomere Length on Allogeneic Transplantation Outcomes: Telomere Length Matters More Than Age
2080 - Epigenetic Reprogramming By Histone Deacetylase Inhibitors Improves CAR-T Cell Functions
2675 - Nlrc3 Signaling Is Indispensable for Hematopoietic Stem Cell Emergence Via Notch Signaling in Vertebrates
4823 - Autophagy Inhibition Prevents CAR-T Exhaustion and Terminal Differentiation Via TCF7 Accumulation
4890 - Constructing a Machine Learning-Based Rating Model to Predict the Outcome of GCSF Mobilization of Hematopoietic Stem Cells in Peripheral Blood
Qian, S.
304 - A Multicenter, Open-Label, Single-Arm, Phase Ib Clinical Trial of HH2853 in the Treatment of Patients with Relapsed and/or Refractory Peripheral T-Cell Lymphoma
Qian, S.
4653 - A Single Center Real World Study of Outcome and Resistance of Bruton Tyrosine Kinase Inhibitors (BTKi) in Chinese Patients with Chronic Lymphocytic Leukeima/Small Lymphocytic Lymphoma
Qian, S.
869 - Olverembatinib (HQP1351) Demonstrates Efficacy Vs. Best Available Therapy (BAT) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic Myeloid Leukemia Chronic-Phase (CML-CP) in a Registrational Randomized Phase 2 Study
Qian, S.
1797 - Flumatinib Versus Nilotinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
3171 - Evaluating Effectiveness and Safety of Flumatinib for Chronic Phase Chronic Myeloid Leukemia in (CML-CP) without Optimal Response (Warning, Failure) to Imatinib or/and Dasatinib
Qian, W.
429 - Tumor-Infiltrating Normal B Lymphocytes Have Remarkable Prognostic Effects and Are Crucial for Antitumor Immune Responses in Diffuse Large B-Cell Lymphoma
2094 - A Phase 1 Study of RJMty19: Anti-CD19 Humanized CAR-Engineered Allogeneic Double Negative T Cells in Adults with B-Cell Non-Hodgkin's Lymphoma
3468 - CD27-Armored BCMA-CAR T Cell (CBG-002) Therapy for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial
Qian, W.
1900 - Updated Efficacy and Safety Results of Lisaftoclax (APG-2575) in Patients (Pts) with Heavily Pretreated Chronic Lymphocytic Leukemia (CLL): Pooled Analyses of Two Clinical Trials
3139 - A Phase I/II Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BTK Inhibitor HZ-a-018 in Adult Patients with Relapsed and/or Refractory Central Nervous System Lymphoma
Qian, Y.
3636 - Pirtobrutinib, a Non-Covalent (reversible) BTK Inhibitor, in Mantle Cell Lymphoma Patients Previously Treated with a Covalent BTK Inhibitor: Results from a China Phase 2 Study
Qian, Y.
1578 - Targeting HDAC9 Contributes to Degradation of MLL Fusion Oncoproteins in KMT2A-Rearranged Acute Myeloid Leukemia
5010 - STI-8591, a Novel Tyrosine Kinase Inhibitor, Shows Excellent Antileukemic Activity in FLT3-Mutated (mut) Acute Myeloid Leukemia (AML)
Qian, Y.
5019 - Machine Learning-Facilitated Cross-Panel Automatic Classification at Both Sample and Cell Level in Acute Myeloid Leukemia
Qian, Z.
304 - A Multicenter, Open-Label, Single-Arm, Phase Ib Clinical Trial of HH2853 in the Treatment of Patients with Relapsed and/or Refractory Peripheral T-Cell Lymphoma
524 - CD58 Genetic Alterations and Its Contribution to Upregulation of PD-L1 and IDO Via LYN/CD22/SHP1 Axis in DLBCL
1719 - GB261, an Fc-Function Enabled and CD3 Affinity De-Tuned CD20/CD3 Bispecific Antibody, Demonstrated a Highly Advantageous Safety/Efficacy Balance in an Ongoing First-in-Human Dose-Escalation Study in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma
3076 - Azacitidine for Injection Combined with Chidamide in Relapsed/Refractory Peripheral T-Cell Lymphoma: A Phase I Study
Qiang, W.
1022 - Updated Results of a Phase I Open-Label Single-Arm Study of Dual Targeting BCMA and CD19 Fastcar-T Cells (GC012F) As First-Line Therapy for Transplant-Eligible Newly Diagnosed High-Risk Multiple Myeloma
Qiao, C.
4642 - Orelabrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (OFCG) for First-Line Treatment of Chronic Lymphocytic Leukemia: A Multicenter, Investigator-Initiated Study (cwCLL-001 Study)
Qiao, J.
281 - Notch1 Regulates Hepatic Thrombopoietin Production
4519 - The Function and Mechanism Research of NLRP6 in Bone Marrow Microenvironment in Myeloproliferative Neoplasms
4844 - Efficacy and Safety of BCMA-Specific CAR T Cell-Based Therapy in Relapsed/Refractory Multiple Myeloma Patients with Extramedullary Disease
Qiao, J.
2971 - Metabolomic Insights into the Pathogenesis and Prognostic Potential of Adult Acute Lymphoblastic Leukemia
Qiao, M.
4922 - Sitagliptin for Prevention of aGVHD in Patients Received Alternative Donor Transplantations: A Prospective, Multicenter, Open-Label, Randomized Controlled Trial
Qiao, N.
1415 - AML Immunotherapy Using a Novel Tcrm-Based Bispecific Antibody That Targets a Leader Sequence Peptide Derived from Cathepsin G
Qiao, Q.
3114 - The Construction of Novel Risk Scores in Diffuse Large B-Cell Lymphoma with Diabetes and the Identification of Glycosylation-Related Prognostic Biomarkers
Qiao, W.
3228 - Oral Decitabine/Cedazuridine with Venetoclax in High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia: Analysis By Different Response Criteria
3238 - Results of Phase I/II Study of Azacitidine in Combination with Quizartinib for Patients with Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms with FLT3 or CBL Mutations
Qiao, Y.
1893 - Single-Cell Long-Read Sequencing Enables the Dissection of BTK Subclonal Dynamics in CLL Treatment
Qin, H.
2044 - Clonal Expansion and Differentiation of Stem-like Memory T Cells to Tissue-Resident Memory T Cells Perpetuates Pathogenesis of Chronic Graft-Versus-Host Disease
Qin, J.
4372 - Validation of Circulating Tumor DNA As an Alternative to Tumor Tissue Biopsy in Genotyping across Multiple Lymphoma Subtypes
Qin, J.
2822 - Preclinical Study of DZD8586, a Non-Covalent LYN/BTK Dual Inhibitor with Excellent BBB Penetration, for the Treatment of B-Cell Non-Hodgkin Lymphoma (B-NHL)
Qin, K.
1101 - Genome-Scale CRISPR-Cas12a Screen Identifies Novel Fetal Hemoglobin Regulators
Qin, L.
890 - A Phase 1 Dose Escalation Trial of Third-Generation CD19-Directed CAR T-Cells Incorporating CD28 and Toll-like Receptor 2 (TLR2) Intracellular Domains for Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas (ENABLE)
Qin, L.
89 - Single Cell Multi-Omic Analysis of Tumor Microenvironment Evolution across the Disease Spectrum of Multiple Myeloma Identifies Differential Mechanisms of Immune Suppression
3302 - Caseinolytic Mitochondrial Matrix Peptidase Proteolytic Subunit (CLPP) As a Novel Mediator of, and Target in High Risk Multiple Myeloma
Qin, L.
4072 - Mapping the Cellular Biogeography of Human Bone Marrow Niches Using Single-Cell Transcriptomics and Proteomic Imaging
Qin, M.
2076 - CD19-CAR T Cytotoxicity Is Improved By AMPKγ2 Overexpression, Which Is Further Enhanced By Metformin Treatment
Qin, S.
1709 - Clinical Features and Therapeutic Evaluation of Central Nervous System Involvement in Pediatric Anaplastic Large Cell Lymphoma
4489 - Clinical Pathology Characteristics of 221 Pediatric Anaplastic Large Cell Lymphoma-3 Years Follow up and Experience from China Net Childhood Lymphoma(CNCL)
Qin, S.
4642 - Orelabrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (OFCG) for First-Line Treatment of Chronic Lymphocytic Leukemia: A Multicenter, Investigator-Initiated Study (cwCLL-001 Study)
4653 - A Single Center Real World Study of Outcome and Resistance of Bruton Tyrosine Kinase Inhibitors (BTKi) in Chinese Patients with Chronic Lymphocytic Leukeima/Small Lymphocytic Lymphoma
Qin, T.
1875 - Comparison of the 2022 ICC and Who Classification Systems of Myelodysplastic Neoplasms
Qin, X.
2543 - Clinical Characteristics of Shwachman–Diamond Syndrome in China — Result from Childhood Bone Marrow Failure Diseases Register of China Alliance for Blood Diseases(cBMFR-CABD)
Qin, X.
513 - Impaired Efficacy and Durability of Hematopoietic Stem Cell Engraftment Caused By Samd9l-Deficiency within Bone Marrow Niches
3615 - One-Stop No-Edited Allogenic CAR-T Therapy Bridging HSCT to Treat Children with Relapse and Refractory Acute Lymphoblastic Leukemia: A Prospective Clinical Study from a Single Center
Qin, X.
3377 - Updated Results of Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma with Prior Exposure to T-Cell Redirecting Therapies: Results of the Phase 1/2 MonumenTAL-1 Study
Qin, Y.
3133 - Early and Sustained Circulating Tumor DNA Response Dynamics after Loncastuximab Tesirine for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Qin, Y.
1481 - Cytoreductive Chemotherapy in Induction Therapy Plays a Key Role in the Prognosis of Patients with Low-Risk Acute Promyelocytic Leukemia
1525 - Comparison of Safety and Efficacy between Venetoclax Combined with CAG (cytarabine, aclarubicin, G-CSF) Regimen and CAG Regimen Alone in Patients with Relapsed or Refractory Acute Myeloid Leukemia
2949 - Trinary Fusion with Ligand Binding Domain Castration Is Crucial in Rarg-Driven APL and Render Unresponsive to ATRA Via Allosteric Disability Mechanism
4288 - A Completely Oral Regimen Including Oral Etoposide As Cytoreductive Chemotherapy Combined with All Trans Retinoic Acid and Oral Arsenic for Induction Therapy in Patients with High-Risk APL：Comparable to Intravenous Cytoreductive Therapy
Qin, Y.
3024 - Safety and Efficacy of Relmacabtagene Autoleucel (relma-cel) in Adults with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL): Updated Results from a Phase II Open-Label Study in China
Qin, Y.
4672 - Lbl-034, a Highly Differentiated T-Cell Engaging Bispecific Antibody Targeting GPRC5D for the Treatment of Relapsed or Refractory Multiple Myeloma
Qing, Y.
1427 - Metformin Potentiates Gilteritinib Sensitivity Via Targeting PLK1 Signaling: A Strategy to Improve Outcomes and Reduce Costs in Treating FLT3-Mutated Acute Myeloid Leukemia
Qingsong, G.
845 - STAG2/LMO2 Gamma-Delta (γδ) T-ALL: Identification and Characterization of an Extremely High Risk Group of T-ALL in the Very Young
Qipo, T.
1149 - Evaluating the Effectiveness of COVID-19 Vaccines in Adults with Sickle Cell Disease during the Omicron Period of COVID-19 Pandemic
Qiu, A.
3023 - Impact of Early Histological Transformation on Survival in Patients with Follicular Lymphoma
Qiu, C.
879 - The Specific Transcriptional Signature and Clonal Selection of MGUS-like Profile Predict an Exceptionally Favorable Prognosis in Patients with Newly-Diagnosed Multiple Myeloma
Qiu, C.
834 - Venetoclax Plus Azacitidine, Low Dose Cytarabine, Aclarubicin and G-CSF (VA-CAG Regimen) for Newly Diagnosed Young Patients with Acute Myeloid Leukemia: A Prospective, Multicenter, Single-Arm Phase 2 Clinical Trial
Qiu, G.
289 - [CANCELED] CD74+ Leukemia-Associated Macrophages Supporess T Cell Immune Surveillance and Promote Leukemic Cell Growth in Acute Myeloid Leukemia
3906 - Single-Cell RNA Sequencing Reveals Contradictory Immune Microenvironment in Hemophagocytic Syndrome
Qiu, H.
4642 - Orelabrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (OFCG) for First-Line Treatment of Chronic Lymphocytic Leukemia: A Multicenter, Investigator-Initiated Study (cwCLL-001 Study)
Qiu, H.
970 - Comparing the Efficacy and Safety of Venetoclax Combined with Decitabine Versus Conventional Chemotherapy As Induction Therapy for Young Adults with Newly Diagnosed Acute Myeloid Leukemia - Interim Analysis of a Multicenter, Randomized, Phase 2b Trial
1528 - Improved Prevention and Treatment Strategy of Differentiation Syndrome Contribute to Reduce Early Death of Patients with Acute Promyelocytic Leukemia
4243 - Reduced-Dose Chemotherapy Followed By Blinatumomab As Induction Therapy in Treatment of Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia - Interim Results from a Multicenter, Single-Arm, Phase 2 Study
4335 - All-Trans-Retinoic Acid Induction Overcomes Immune Evasion through Downregulating Immune Checkpoint Molecules and Inducing a Cytokine Storm Triggered By Overexpression of S100A8/A9 Signaling
4922 - Sitagliptin for Prevention of aGVHD in Patients Received Alternative Donor Transplantations: A Prospective, Multicenter, Open-Label, Randomized Controlled Trial
Qiu, H.
3554 - A Novel JAK1 Inhibitor SHR0302 for Treatment of Chronic Graft-Verse-Host Disease: A Phase I Clinical Trial
Qiu, H.
889 - Efficacy and Safety of Interleukin-6-Knockdown CD19-Targeted CAR T Cells(ssCART-19) for Relapsed/Refractory B-ALL
3477 - Phase I Open-Label Single-Arm Study of Sscart-19 in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in China
3491 - Efficacy and Safety of the Second CAR-T Therapy in Patients with Refractory/Relapsed Acute B-Cell Lymphoblastic Leukemia
Qiu, L.
524 - CD58 Genetic Alterations and Its Contribution to Upregulation of PD-L1 and IDO Via LYN/CD22/SHP1 Axis in DLBCL
1677 - PI3Kδ Inhibitor Linperlisib As a ≥ 3-Line Treatment for Relapsed or Refractory Follicular Lymphoma: A Subgroup Analysis of a Phase II, Single-Arm, Open-Label Trial
3076 - Azacitidine for Injection Combined with Chidamide in Relapsed/Refractory Peripheral T-Cell Lymphoma: A Phase I Study
4430 - Phase 2 Study of Golidocitinib, a JAK1 Selective Inhibitor, As Maintenance Therapy in Patients with Peripheral T Cell Lymphomas after First-Line Systemic Therapy (JACKPOT26)
Qiu, L.
736 - A Prospective Multicenter Phase II Study of Orelabrutinib-Lenalidomide-Rituximab (OLR) in Patients with Untreated Mantle Cell Lymphoma (MCL) in China (POLARIS Study): Preliminary Analysis on Efficacy, Safety, Mutation Spectrum and Impact of Mutation Profiling on Treatment Responses
Qiu, L.
218 - Naturally Selected CD7-Targeted Chimeric Antigen Receptor (CAR)-T Cell Therapy for Refractory/Relapsed Acute Myeloid Leukemia: Phase I Clinical Trial
Qiu, L.
202 - Extended Follow-up of ALPINE Randomized Phase 3 Study Confirms Sustained Superior Progression-Free Survival of Zanubrutinib Versus Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL)
306 - A Multicenter Phase2 Trial of Linperlisib in Relapsed or Refractory Peripheral T/NK Cell Lymphomas
761 - Efficacy Outcomes and Characteristics of Patients with Multiple Myeloma (MM) Who Achieved Sustained Minimal Residual Disease Negativity after Treatment with Equecabtagene Autoleucel (Eque-cel, CT103A) in Fumanba-1
879 - The Specific Transcriptional Signature and Clonal Selection of MGUS-like Profile Predict an Exceptionally Favorable Prognosis in Patients with Newly-Diagnosed Multiple Myeloma
1649 - Classification of NK-Large Granular Lymphocytic Leukemia By CD56 Expression
1677 - PI3Kδ Inhibitor Linperlisib As a ≥ 3-Line Treatment for Relapsed or Refractory Follicular Lymphoma: A Subgroup Analysis of a Phase II, Single-Arm, Open-Label Trial
1722 - A Phase Ib Study of Linperlisib Monotherapy in Patients with Relapsed or Refractory B-Cell Malignancies
1732 - Linperlisib in Conjunction with Gemcitabine and Oxaliplatin in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Multicenter, Single-Arm Phase Ib/II Study
1890 - Acquired Mutations in Patients (Pts) with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) That Progressed in the ALPINE Study
1920 - Monitoring Minimal Residual Disease in Patients with Multiple Myeloma By Tracking Serum M-Protein Using Mass Spectrometry
1955 - Hyposecretory Progression Pattern Indicates Inferior Survival of Multiple Myeloma
1967 - Development and Validation of an Individualized and Weighted Prognostic Model in Patients with Newly Diagnosed Multiple Myeloma
1978 - A Phase 1 First-in-Human Monotherapy Study of F182112, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed or Refractory Multiple Myeloma
3038 - The Prognostic Impact of Measurable Residual Disease Dynamics in Mantle Cell Lymphoma
3048 - Development and Validation of a Machine-Learning Model to Predict POD24 Risk of Follicular Lymphoma
3482 - Comparison of Efficacy and Side Effects of BTK Inhibitors for Different Duration As a Bridging Therapy before Anti-CD19-CAR T-Cell Therapy in Patients with R/R DLBCL
4368 - Proteogenomic Features Define Novel Subtypes of Mantle Cell Lymphoma
4661 - Enhanced Expression of DNp73 Promotes Drug Resistance and Immune Evasion in Multiple Myeloma By Targeting the MYC and MYCN Pathways
4667 - Identification of Therapy-Induced Clonal Evolution and Resistance Pathways in MRD Clones in Multiple Myeloma through Single-Cell Sequencing
Qiu, Q. C.
4216 - RUNX1 Mutation Does Not Significantly Impact the Outcome of Newly Diagnosed adult AML: A Retrospective Study of Chinese AML Patients
Qiu, S.
827 - Olverembatinib Combined with Venetoclax and Reduced-Intensity Chemotherapy for Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Early Results from a Phase II Study
2750 - IKZF2 Specifically Participates in AML1-ETO Mediated Blockage of Myeloid Differentiation
4129 - AML1-ETO and CCND2 Overexpression­ Cooperate to Drive AML Initiation and Progression
4209 - The Impact of ZNF384 Rearranged on Antigen Editing during Treatment-Specific Selective Pressures in Adult B Cell Acute Lymphoid Leukemia
Qiu, T.
4642 - Orelabrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (OFCG) for First-Line Treatment of Chronic Lymphocytic Leukemia: A Multicenter, Investigator-Initiated Study (cwCLL-001 Study)
4653 - A Single Center Real World Study of Outcome and Resistance of Bruton Tyrosine Kinase Inhibitors (BTKi) in Chinese Patients with Chronic Lymphocytic Leukeima/Small Lymphocytic Lymphoma
Qiu, X.
2094 - A Phase 1 Study of RJMty19: Anti-CD19 Humanized CAR-Engineered Allogeneic Double Negative T Cells in Adults with B-Cell Non-Hodgkin's Lymphoma
3468 - CD27-Armored BCMA-CAR T Cell (CBG-002) Therapy for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial
Qiu, X.
4057 - New Insights into Hematopoietic Redefinition and New Paradigms in Hematopoietic Hierarchy Roadmap
Qiu, Y.
3481 - Safety and Efficacy of CD22/ CD19 CAR-T and Auto-HSCT “Sandwich" Strategy As Consolidation Therapy for Ph Negative B Cell Acute Lymphoblastic Leukemia
4216 - RUNX1 Mutation Does Not Significantly Impact the Outcome of Newly Diagnosed adult AML: A Retrospective Study of Chinese AML Patients
Qiu, Y.
1077 - Ncrna-a3 Epigenetically Regulates TAL1 and Its Target Genes to Drive Erythroid Differentiation
2456 - GATA-1 and BCL11A Collaboratively Regulate Erythroid Gene Expression through HDAC1 Dependent Manner
Qiu, Y.
165 - Optimizing FLT3 Inhibitor Use in Adult Acute Myeloid Leukemia with FLT3 Mutations Using Proteomics
1581 - Proteomic Profiling Identifies Unique IDH Mutant Signatures and Novel Therapeutic Opportunities in Adult Acute Myeloid Leukemia Patients
2787 - A STAT3 Degrader Demonstrates Pre-Clinical Efficacy in Venetoclax Resistant Acute Myeloid Leukemia
Qiu, Y.
550 - Intensive Chemotherapy (IC) Followed By Oral Azacitidine (AZA) Maintenance Versus Venetoclax (VEN) Plus AZA for Patients (pts) with Acute Myeloid Leukemia (AML): Retrospective Analysis of an Electronic Medical Record (EMR) Database in the United States
593 - Treatment Patterns and Outcomes of Patients with Acute Myeloid Leukemia (AML) from 2013 to 2022: A Connect® Myeloid Registry Study
Qiu, Y.
597 - A Specialized CD4+ T-Cell Subset Protects Residual Leukemic Cells from Immune Surveillance, Enabling Relapse
Qu, C.
1658 - Zr Study: A Prospective Phase II Study of Zanubrutinib-Rituximab Chemo-Free Therapy with or without Autologous Stem Cell Transplantation in Newly Diagnosed Mantle Cell Lymphoma
Qu, C.
845 - STAG2/LMO2 Gamma-Delta (γδ) T-ALL: Identification and Characterization of an Extremely High Risk Group of T-ALL in the Very Young
Qu, J.
3613 - Long-Term Outcome of a Unique Haploidentical High-Dose Peripheral Stem Cell Transplantation Protocol for Hematologic Malignancies: A Prospective Single-Center Study
Qu, L.
1709 - Clinical Features and Therapeutic Evaluation of Central Nervous System Involvement in Pediatric Anaplastic Large Cell Lymphoma
4489 - Clinical Pathology Characteristics of 221 Pediatric Anaplastic Large Cell Lymphoma-3 Years Follow up and Experience from China Net Childhood Lymphoma(CNCL)
Qu, Q.
803 - Prednisone Plus Ivig Compared with Prednisone for Immune Thrombocytopenia during Pregnancy
2194 - Donor Macrophage Pyroptosis Contributed to the Development of aGVHD
2588 - Terbutaline Modulates Macrophage Homeostasis and Macrophage-T-Cell Interactions in Immune Thrombocytopenia
3951 - Biomarker MSC-C5b-9-Guided Master Therapies for Resistant/Recurrent ITP: A Prospective, Randomized, Open-Label, Multicenter Trial
Qu, S.
1875 - Comparison of the 2022 ICC and Who Classification Systems of Myelodysplastic Neoplasms
Qu, T.
5089 - Cost-Effectiveness of Epcoritamab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma after at Least Two Lines of Therapy in the United States
Qu, X.
1801 - Dynamic Single-Cell RNA-Seq Reveals Mechanism of Selinexor-Resistance in Chronic Myeloid Leukemia
Qu, X.
1976 - Resistance to CD38 Antigen Targeted Therapy in Multiple Myeloma May Result from Underrecognized Chromosome 4 Gene Deletions
2945 - Prognostic Value of Copy Number Aberrations and Copy Neutral Loss of Heterozygosity in Acute Myeloid Leukemia
Quach, D. T.
4183 - Novel Protac-Based EZH2 Degraders Effectively Target EZH2-Driven Lymphoid Malignancies By Abolishing Both Methylation-Dependent and -Independent Functions
Quach, H.
338 - Venetoclax in Combination with Daratumumab and Dexamethasone Elicits Deep, Durable Responses in Patients with t(11;14) Relapsed/Refractory Multiple Myeloma: Updated Analyses of Minimal Residual Disease Negativity in Phase 1/2 Study
878 - Cell Free MYC DNA Copy Number Identifies High-Risk Smouldering Myeloma and Newly Diagnosed Multiple Myeloma
1011 - Sonrotoclax (BGB-11417) in Combination with Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma with t(11;14): Safety, Efficacy, and Determination of Recommended Phase 2 Dose
1014 - Talquetamab + Pomalidomide in Patients with Relapsed/Refractory Multiple Myeloma: Safety and Preliminary Efficacy Results from the Phase 1b MonumenTAL-2 Study
2010 - Belantamab Mafodotin in Combination with Lenalidomide Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Safety and Efficacy Analysis of DREAMM-6 Trial Arm-a
2012 - A Phase I/II Single Arm Study of Belantamab Mafodotin, Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: Planned Interim Analysis of Safety and Efficacy. Amarc 19-02 Belacard Study
2019 - Isatuximab Rescue for Inadequate Response to Lenalidomide and Dexamethasone in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma: Primary Analysis of the Phase II Iril Study of the Australian Myeloma Research Consortium (AMaRC 18-02)
2021 - Carfilzomib, Daratumumab, and Dexamethasone (KdD) Vs Carfilzomib and Dexamethasone (Kd) for Relapsed/Refractory Multiple Myeloma (RRMM) in the Phase 3 Candor Study: Subgroup Analysis According to Renal Functioning
2023 - Planned Interim Safety Analysis of the Phase 3 Randomized Trial of Selinexor and Lenalidomide Versus Lenalidomide Maintenance Post Autologous Stem Cell Transplant for Patients with Newly Diagnosed Multiple Myeloma (ALLG MM23; Sealand)
3325 - Impact of 1q21 Gain and Amplification on Daratumumab-Treated Multiple Myeloma Patients: Real-World Data from the Australia-New Zealand and Asia-Pacific Myeloma and Related Diseases Registries
3328 - Evaluation of Easym, a Clonotypic Mass Spectrometry Assay, and Euroflow Minimal Residual Disease Assessment in Multiple Myeloma
4707 - Initial Dose Escalation of ISB 1442, a Novel CD38 Biparatopic x CD47 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)
4731 - A Prospective, Multinational Study of Clinical and Biological Factors Associated with Short Overall Survival in Multiple Myeloma
LBA-1 - Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Vrd Alone in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Eligible for Autologous Stem Cell Transplantation (ASCT): Primary Results of the Perseus Trial
Quach, J.
3077 - Preliminary Analysis Demonstrates Durvalumab (Anti-PD-L1) & Lenalidomide Is Superior to Single-Agent Durvalumab (anti-PD-L1) in Refractory/Advanced Cutaneous T Cell Lymphoma in a Randomized Phase 2 Trial
Quach, S.
2209 - High Progression-Free Survival with Low Relapse Rates after Double-Unit Cord Blood Transplantation in Patients with High-Risk AML
4916 - Optimized Double-Unit Cord Blood Transplantation Mitigates Transplant-Related Mortality Resulting in High Progression-Free Survival in Adults with Hematologic Malignancies
Quade-Lyssy, P.
2146 - Automatic Generation of Alloreactivity-Reduced Donor Lymphocytes and Hematopoietic Stem Cells from the Same Mobilized Apheresis Product
Quadri, M.
153 - Biallelic PI4KA mutations Disrupt B Cell Mitochondrial Metabolism and Cause Hypogammaglobulinemia
Quadri, S.
3053 - EPCORE FL-1: Phase 3 Trial of Subcutaneous Epcoritamab with Rituximab and Lenalidomide (R2) Vs R2 Alone in Patients with Relapsed or Refractory Follicular Lymphoma
Quadt, C.
4752 - Initial Results from a Phase 1 Dose-Escalation Study of WVT078, a BCMA×CD3 Bispecific Antibody, in Combination with WHG626, a Gamma-Secretase (GS) Inhibitor, in Patients with Relapsed and/or Refractory Multiple Myeloma
Quagliarella, F.
114 - Emapalumab for Treatment of Impending Graft Failure
3567 - Reconstitution Dynamics and Impact on Clinical Outcomes of Mucosal-Associated Invariant T-Cells in Pediatric Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation
4924 - Improved T- and B-Cell Neogenesis in Children with Acute Leukemia Given an Alpha-Beta T-Cell Depleted Haplo-HSCT Combined with the Infusion of Donor T-Cells Genetically Modified with Inducible Caspase 9 Suicide Gene (Rivo-cel)
Quaglino, P.
1704 - Health-Related Quality of Life (HRQL) in Cutaneous T-Cell Lymphoma: A Post Hoc Analysis Examining Disease Burden and Patient Characteristics from the Phase 3 Mavoric Trial in Mycosis Fungoides and Sézary Syndrome
Qualls, D. A.
312 - Loncastuximab in High-Risk and Heavily-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Real World Analysis from 21 US Centers
3136 - Outcomes of Sequential CD19-Directed Therapies in Relapsed and Refractory Large B Cell Lymphoma
4970 - Responses and Outcomes after Second-Line Therapy in Transplant-Eligible Patients with DLBCL Relapse over 1 Year after First-Line Therapy
Quan, X.
2222 - Clinical Study on the Efficacy and Safety of Peg Rhg CSF for Autologous Hematopoietic Stem Cell Mobilization in Lymphoma and Multiple Myeloma：a Randomized Controlled, Multicenter Clinical Study
Quang Nguyen, V.
3036 - Acalabrutinib with Rituximab As First-Line Therapy for Older Patients with Mantle Cell Lymphoma – a Phase II Clinical Trial
Quang, T.
2492 - Longitudinal Characterization of Hemodynamic Changes with Multimodal Optical Techniques in Patients with Sickle Cell Disease Treated with Mitapivat
3862 - Exploring Near Infrared Spectroscopy As a Tool for Monitoring Tissue Hemodynamics for Patients with Sickle Cell Disease
Quann, K.
458 - TCF-1 is Required By CD8+ T Cells for the Maintenance of Alloimmune Responses in Graft-Vs-Host Disease
4791 - A Novel High-Throughput Method for Identifying T-Cell Receptor: Minor Histocompatibility Antigen Interactions in Mouse Models of Graft-Vs-Host Disease
Quaranta, P.
2692 - Unraveling Pathophysiology and Hematopoiesis of Vexas Syndrome By Multi-Omics Analyses and Targeted Gene Editing
Quarato, E. R.
314 - Isocitrate Dehydrogenase 2 Mutation Allows Myeloid Differentiation but Impairs Bone Marrow Macrophage Polarization and Function Via Metabolic Dysregulation
Quarchione, M.
2220 - High Progression Free Survival Rates in Patients with Multiply Relapsed/Refractory Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplant after Checkpoint Inhibitors: Results from Grupo Argentino De Trasplante De Medula Osea y Terapia Celular (GATMO-TC)
Quarder, M.
630 - Mutation Clearance of Driver Mutations after Transplantation for Myelofibrosis Predicts Outcome
Quaresmini, G.
4232 - Improving Prediction of Early Death in Acute Promyelocytic Leukemia: External Validation Study from Italian Single Center Experience
Quarles, D.
3631 - Feasibility of Extracorporeal Delivery of Fusosomes to Generate CAR T Cells In Vivo
Quarmyne, M. O.
665 - Role of Menstrual Bleeding Assessments in Sickle Cell Clinics in Improving Quality of Care for Women- a Multicenter Approach
Quarta, C. C.
540 - Safety and Tolerability of Cael-101, an Anti-Amyloid Monoclonal Antibody, Combined with Anti-Plasma Cell Dyscrasia Therapy in Patients with Light-Chain Amyloidosis: 24-Month Results of a Phase 2 Study
Quast, L.
3734 - Building Adaptive Coping and Knowledge to Improve Daily Life (Back2Life): A Pilot Feasibility Trial for Youth with Chronic Sickle Cell Pain
Quataert, S. A.
4392 - Splenic B Cell Lymphoma Innate Immune Cells: Detection of Red Versus White Pulp Lymphoma Differences in NK Cell Populations By High-Parameter Flow Cytometry
Quattrone, M.
3801 - Lifestyle Behaviors and Health-Related Quality of Life in Long-Term Survivors of Acute Myeloid Leukemia: An International Survivorship Study By the Gimema, EORTC Quality of Life and Leukemia Groups
Quaye, N.
1150 - Evaluating Different Strategies to Screen for Depression in Sickle Cell Disease
Qubain, M.
4801 - API-192, an Allogeneic CD19/20 CAR-NKT Cell Product Derived from Cord Blood CD34+ HSPCs for the Treatment of B-Cell Malignancies
Queen, J.
929 - SCD Dyslipidemia Normalizes Long-Term Following Nonmyeloablative Hematopoietic Cell Transplantation
Quehenberger, P.
1249 - Impact of Blood Group O and Von Willebrand Factor on Bleeding Severity in Patients with Von Willebrand Disease and Bleeding Disorder of Unknown Cause
Queiroz, C.
3938 - Loss of Platelet 12-Lipoxygenase Aggravates the Severity of Sars-Cov-2 Infection
Queizan Hernandez, J. A.
1616 - Mutually-Exclusive Pathways between IKZF1plus and RAS Mutations and TP53 double-Hit Alterations Lead Relapse in B-Other, Ph-like and Hyperdiploidy Genetic Groups in Adult B-Cell Acute Lymphoblastic Leukemia
4511 - Early Identification of Very High Risk Patients with Diffuse Large B Cell Lymphoma (DLBCL) By PET-CT
Quek, J. K. S.
3601 - Co-Expression of C-MYC/BCL2 Is Associated with Inferior Survival Outcomes in Relapsed/Refractory Diffuse Large B-Cell Lymphoma after Autologous Stem Cell Transplantation – a Nationwide Retrospective Analysis in Singapore
Quek, L.
294 - Metabolism-Related Features Identify the Combination Metformin Plus NAMPT Inhibitors As a Selective Treatment Strategy in Acute Myeloid Leukemia
812 - An Integrated Single Cell Immunogenomic Atlas Reveals Pathways of Clonal Expansion, Inflammation and Dyserythropoiesis in Low and High-Risk Clonal Haematopoiesis
839 - CEBPA-Driven Expression of the Transcriptionally Inactive deltaTP73 Isoform Phenocopies TP53mutated Poor Risk and Drug-Resistant Acute Myeloid Leukemia
1586 - Metformin-Induced Ferroptosis Is a Therapeutic Vulnerability in IDH2-Mutant AML Linked to Metabolic Rewiring Towards Fatty Acid Oxidation
Quek, M. Y.
3728 - Feasibility and Implementation of an out-of-Pocket Cost Calculator for Pre-Treatment Financial Counselling in Cancer Patients
Quentin, J.
3452 - Molecular Attributes of CAR T Cell Fitness in Patients with Chronic Lymphocytic Leukemia
Querbes, B.
2073 - Deploying an RNA-Based Gene Writer System and Lipid Nanoparticle (LNP) Delivery to Generate Functional Chimeric Antigen Receptor (CAR) T Cells with in Vitro and In Vivo Anti-Tumor Activity
Querfeld, C.
381 - Quality of Life and Global Response Score in Cutaneous T-Cell Lymphoma
3077 - Preliminary Analysis Demonstrates Durvalumab (Anti-PD-L1) & Lenalidomide Is Superior to Single-Agent Durvalumab (anti-PD-L1) in Refractory/Advanced Cutaneous T Cell Lymphoma in a Randomized Phase 2 Trial
4856 - Phase 1 Study of Autologous Sirpα-Low Macrophages (SIRPant-M) Administered By Intratumoral Injection Alone or in Combination with External-Beam Radiotherapy in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma (NCT05967416)
Quesada, A. E.
4303 - Optical Genomic Mapping Provides Unique Findings in Various Types of Myeloid Neoplasms
Quesada Sánchez, M.
4490 - Incidence, Management and Outcome of Post-Transplant Lymphoproliferative Disease after 5797 Solid-Organ Transplants over a 30-Year Period in a Single Hospital
Quezada, G.
5149 - Incidence and Management of COVID-19 Infections in Vaccinated Patients with CLL
Quezado, Z.
2482 - 8-Oxoguanine DNA Glycosylase 1 Inhibition Suppresses Inflammatory Responses in Sickle Cell Disease
Quezado, Z.
3858 - Exploring Mitochondrial DNA Heteroplasmy in a Mouse Model of Sickle Cell Disease
3935 - NLRP3 Inflammasome-Mediated Platelet Activation and Thrombus Formation in Sickle Cell Mice Can be Targeted By the BTK Inhibitor Ibrutinib
Quigley, J.
374 - Individual-Level Social Determinants of Health (SDOH) Measures and Treatment Complications in Acute Leukemia
2630 - Extended Thromboprophylaxis in Patients Hospitalized with COVID-19 at Time of Discharge from the Hospital Is Not Associated with an Improvement in Quality of Life: Results from the Activ 4c Clinical Trial
3395 - Free from Drug Therapy in Multiple Myeloma (FREEDMM): MRD-Based Cessation of Maintenance
4897 - Addition of Myeloablative Doses of Total Marrow Irradiation (TMI) to Myeloablative Fludarabine/Busulfan Conditioning for Allogeneic HSCT in Patients with High-Risk AML, CML, or Myelodysplastic Syndrome: A Phase II Clinical Trial
Quigley, M. T.
3391 - Trial in Progress: A Phase 1 Study of KTX-1001, an Oral, First-in-Class, Selective MMSET Inhibitor in Patients with Relapsed and Refractory Multiple Myeloma
Quignot, N.
4016 - Management and Evolution after VTE Recurrence and/or Bleeding in Cancer Patients Receiving Anticoagulant Therapy for VTE: A Nationwide Cohort Study in France
Quijada Álamo, M.
1886 - ZMYM3 Mutations Cooperate with NOTCH1 Alterations, Reduce Histone H4 Acetylation and Promote Apoptosis Evasion in Chronic Lymphocytic Leukemia
1889 - TRAF3-Inactivated Chronic Lymphocytic Leukemia Cells Show an Enhanced Metabolic Plasticity That Can be Attenuated By Glutaminolysis and Mitochondrial Pyruvate Import Inhibition
Quill, T. A.
3716 - Determining Clinical Practice Gaps for HCPs in Treating CLL Using CME-Based Surveys
5046 - A Novel Online Decision Support Tool to Determine Practice Patterns and Concordance with Experts in the Treatment of Patients with Immune Thrombocytopenia
Quillen, L.
910 - Comprehensive Analysis of Structural and Social Determinants of Health Leading to Delays in Seeking Hematologic Care: Survey of an Underserved Population with Hematologic Malignancies
Quin, C.
938 - Chronic TNF in the Aging Microenvironment Exacerbates TET2-loss-of-Function Myeloid Expansion
Quinn, C. T.
1145 - Effects of L-Glutamine on Biomarkers of Response in Sickle Cell Disease: A Pharmacokinetics-Pharmacodynamics Analysis
3874 - Association between Acute Pain Scores in Children with Sickle Cell Disease and Emergency Department Disposition and Return Visit Rates
Quinn, D.
3132 - An International Multicenter Study of Primary Vitreoretinal Lymphoma from the Australasian Lymphoma Alliance and Collaborators
Quinn, D.
3469 - T-Charge™ Manufacturing of the Anti-BCMA CAR-T, Durcabtagene Autoleucel (PHE885), Promotes Expansion and Persistence of CAR-T Cells with High TCR Repertoire Diversity
Quinn, F.
200 - Laboratories Can Reliably Detect Clinically Relevant Variants in the TP53 Gene below 10 % Allelic Frequency: A Multicenter Study of ERIC, the European Research Initiative on CLL
Quinn, K.
703 - Clinical Manifestations Are Evolving and Progressive in Patients with Vexas Syndrome
Quinn, S. C.
3771 - The Additional Disease Burden Accompanying a Delayed Diagnosis of Multiple Myeloma: Utilising a Large Real-World Evidence Base
Quino, K.
3294 - Gut Microbiota Diversity and Composition Is Associated with High-Risk Myeloma
Quinones Raffo, D.
4085 - Characterization of Hematopoietic Stem and Progenitor Cells of PNH Patients Using Single-Cell RNA Sequencing Analysis
Quiñones, S.
4225 - LONG-TERM Outcomes after Venetoclax-Hypomethylating Agent Combination Therapy Discontinuation, in Patients with ACUTE Myeloid Leukemia. Experience of a Single Center
Quiñones, T.
4225 - LONG-TERM Outcomes after Venetoclax-Hypomethylating Agent Combination Therapy Discontinuation, in Patients with ACUTE Myeloid Leukemia. Experience of a Single Center
Quiñonez, J. M.
1503 - Survival Analysis of Adults with Acute Lymphoblastic Leukemia in Ecuador
Quinquenel, A.
3268 - Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Interim Results of MRD Kinetics in the Eradic Trial from the Filo Group
Quintela, D.
3244 - Molecular Classification of Chronic Myelomonocytic Leukemia: Results of the Analysis of an International Cohort of 2,471 Patients
Quintela González, M. D. C.
2346 - The Frailty Syndrome As Predictor of Allogeneic Hematopoietic Cell Transplantation Outcomes. Prospective Study on Behalf of the Grupo Español De Trasplante Hematopoyético y Terapia Celular
3702 - Frailty Syndrome in Adults Undergoing Autologous Hematopoietic Cell Transplantation. Prospective Study on Behalf of the Grupo Español De Trasplante Hematopoyético y Terapia Celular
Quinten, E.
1885 - B-Cell Receptor Function and Gene Expression Profiling at Single-Cell Level across the Spectrum from Normal to Neoplastic CD5-Positive B-Cell Compartments in Humans
4139 - Detection of Occurrent Somatic Hypermutation and Associated Gene Expression Profile in Single B Cells
Quintero, G.
2855 - Real-World Study in Acute Leukemia: Epidemiology, Treatment Patterns and Outcomes for Newly Diagnosed AML in Adult Patients from Latin America – Loyal Study
Quintero, H. I.
1748 - Real-World Data on the Clinical Features, Therapy Patterns and Outcomes of 651 Elderly Patients with Diffuse Large B-Cell Lymphoma in Latin America: A Study from the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL)
1757 - Validating the Halp Score (Hemoglobin,Albumin, Lymphocytes, and Platelets) and the Neutrophil/Lymphocyte Ratio (NLR) As Prognostic Factors for Overall Survival in Patients with Diffuse Large B-Cell Lymphoma. Retrospective Analysis By the Grupo De Estudio De Latino America De Linfoproliferativos (GELL)
1775 - Validating the Systemic Inmmune-Inflamation Index (SII) As a Prognostic Biomarker of Overall Survival in Diffuse Large B-Cell Lymphoma: A Retrospective Analyses By the Gruppo De Estudio Latinoamericano De Linfoproliferativos (GELL)
4441 - Clinical Features, Treatment Patterns and Outcomes of 864 Newly Diagnosed Hodgkin Lymphoma Patients in Latin America and the Impact of PET Scan Availability on Survival: A Study from the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL)
Quintessenza, J.
1284 - Incidence and Timing of Thromboembolism in Pediatric Patients with Congenital Heart Disease Undergoing Cardiac Surgery: A Single Center Retrospective Study
2647 - Recurrent Thromboembolism in Patients with Congenital Heart Disease and Prior Thromboembolism: A Prospective Cohort Study
Quinti, E.
4215 - The Impact of Baseline Genetic Profile and Treatment on Hematological Toxicity in CEBPA-Mutated Acute Myeloid Leukemia
4224 - APL-like Subset within NPM1-Mutated Acute Myeloid Leukemia: A Distinct Phenotypic Signature Correlating with Early-Onset Vascular Complications
Quintino, S.
2475 - Luspatercept in the Treatment of Beta Thalassemia in Italy: Lights and Shadows in Clinical Practice
Quiros, P.
863 - Polygenic Germline Risk of Common Haematological Traits Drives Clonal Selection on JAK2V617F and Development of Myeloproliferative Neoplasms
1318 - Machine Learning for Identification of High-Risk Clonal Haematopoiesis Using Blood Count Data
Quiroz, A. R.
186 - Epidemiology, Clinical Features and Outcomes of Peripheral T-Cell Lymphoma in Latin America
4441 - Clinical Features, Treatment Patterns and Outcomes of 864 Newly Diagnosed Hodgkin Lymphoma Patients in Latin America and the Impact of PET Scan Availability on Survival: A Study from the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL)
Quiroz, F. F.
2410 - Multiple Myeloma Patient Perceptions of Minimal Residual Disease Testing
3598 - Age-Based Comparison of Stem Cell Transplantation during the First Line of Therapy for Multiple Myeloma Patients
Quispe, I.
2951 - Multiomics Characterization of Normal CD34+ Hematopoietic Progenitor Cells (HPC) and Blasts in the Bone Marrow (BM) and Peripheral Blood (PB) of Patients with Acute Myeloid Leukemia (AML)
Quist-Løkken, I.
4660 - Genome-Wide CRISPR/Cas9 Knock-out Screen Identifies Apoptosis-Relevant Genes in Multiple Myeloma
Quittet, P.
445 - Trial of Imatinib after Ponatinib Induction (TIPI) in the Front-Line Treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Setting. Report of the First Therapeutic Sequence
1717 - Tislelizumab, an Anti-PD1 Antibody, in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma in Tirhol Bgb-A317-210: A Prospective Multicenter Lysa Phase 2 Study Conducted in Western Countries
Quivoron, C.
4064 - Mutational Profile and Dynamics of PPM1D-Mutant Clones in the Spectrum of Myeloid Disorders
Qureshi, A.
2831 - Title: Risk Factors and Natural History of Vincristine Induced Neuropathy on UKALL 2011: A Randomised Controlled Trial of the Effect of Omitting Vincristine Pulses
Qureshi, Q. U. A.
1399 - Hnrnpu mutations Are Haploinsufficient and Alter the Transcriptome of MYC-Driven Lymphomas
Qureshi, Z. P.
270 - Comparative Effectiveness of Ibrutinib Flexible Dosing Treatment Strategies on Time to Next Treatment in a Largely Community-Based Claims Database: A Target Trial Emulation Study
1915 - Ibrutinib Dose Adjustment Does Not Impact Time to Next Treatment in First-Line Patients with Chronic Lymphocytic Leukemia: A Real-World Analysis of Electronic Medical Records from Academic and Non-Teaching Hospitals Using Target Trial Emulation
3278 - Overall Survival Outcomes in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Patients with High-Risk Molecular-Cytogenetic Features Treated with 1L Ibrutinib: A Comparative Effectiveness Study Using the Flatiron Health Data
Quy, R.
5069 - Exploring the Utility and Significance of an Adult Academic Non-Cancer Hematology Clinic
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z